Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

  • Revenue in EUR (TTM)37.65bn
  • Net income in EUR11.22bn
  • Incorporated1994
  • Employees100.41k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
announced
Transaction
value
Kiadis Pharma NVAnnounced02 Nov 202002 Nov 2020Announced8.57%254.17m
Principia Biopharma IncDeal completed17 Aug 202017 Aug 2020Deal completed-1.71%3.67bn
Synthorx IncDeal completed09 Dec 201909 Dec 2019Deal completed0.53%2.45bn
Data delayed at least 15 minutes, as of Dec 02 2020 09:31 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lonza Group AG5.54bn779.81m39.05bn15.91k50.196.5256.867.0511.3511.0380.6687.330.4387----389,061.306.185.237.346.5138.7236.1714.0911.13--10.880.368533.946.8210.2216.3426.3134.293.50
GlaxoSmithKline plc38.08bn7.08bn76.40bn99.44k10.824.819.612.011.271.276.812.850.41741.664.28344,529.708.617.6213.6112.6668.0768.6220.6314.920.60610.680.578102.319.527.9732.7911.004.320.00
Novo Nordisk A/S17.09bn5.58bn102.20bn44.33k23.7216.2116.085.9817.7017.7054.1925.880.96071.165.432,979,299.0031.3737.4163.5070.3583.6984.4032.6533.350.783120.970.064549.709.116.560.83628.0220.9710.80
Sanofi SA37.65bn11.22bn106.65bn100.41k9.50--8.432.838.928.9129.97--------374,966.40--3.69--4.3967.6668.3728.8310.78--36.48--96.705.483.30-32.69-7.414.562.02
AstraZeneca plc21.59bn2.08bn113.79bn70.60k54.6411.1821.675.271.431.4314.796.980.42061.514.73275,086.403.933.845.595.3480.0981.469.3410.080.76463.320.6213144.6210.38-1.69-38.051.60-2.220.6658
Data as of Dec 02 2020. Currency figures normalised to Sanofi SA's reporting currency: Euro EUR

Institutional shareholders

13.37%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Oct 202032.56m2.59%
Norges Bank Investment Managementas of 31 Dec 201926.69m2.12%
Fidelity Management & Research Co. LLCas of 30 Sep 202020.20m1.60%
BlackRock Fund Advisorsas of 05 Nov 202016.80m1.33%
Dodge & Coxas of 30 Sep 202014.55m1.16%
Amundi Asset Management SA (Investment Management)as of 24 Nov 202013.92m1.11%
Lyxor International Asset Management SASas of 25 Nov 202013.69m1.09%
BNP Paribas Asset Management France SASas of 05 Nov 202010.38m0.83%
FIL Investment Advisors (UK) Ltd.as of 30 Sep 20209.75m0.78%
BlackRock Advisors (UK) Ltd.as of 05 Nov 20209.73m0.77%
More ▼
Data from 31 Dec 2019 - 25 Nov 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.